Gamida Cell Appoints Terry Coelho as CFO
May 22 2023 - 8:00AM
Business Wire
Industry veteran Coelho brings more than 35
years of experience at emerging growth and global companies to
role; Shai Lankry to leave company June 2
Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working
to turn cells into powerful therapeutics, today announced the
appointment of Terry Coelho as Chief Financial Officer effective
immediately. Shai Lankry, who has served as the company’s CFO for
the past five years, is stepping down as CFO today and will leave
the company June 2.
The transition is part of a planned leadership change first
shared with the investor community in August 2022 and designed to
coincide with Gamida Cell’s evolution from a clinical to a
commercial-stage company. Ms. Coelho is a seasoned finance
executive with more than 35 years of experience across all areas of
finance at emerging growth companies and established global
companies.
“I want to thank Shai for his many contributions supporting the
expansion and evolution of the company to include a more robust
pipeline and operations in both the United States and Israel,” said
Abbey Jenkins, President and Chief Executive Officer. “Terry has
tremendous experience as CFO of commercial-stage biopharmaceutical
companies. She will be a great partner to help us execute our
two-pronged strategy of launching Omisirge and, in parallel,
pursuing strategic partnerships to fully resource
commercialization.”
Ms. Coelho currently serves as an independent director on the
public company boards of First Wave BioPharma (Nasdaq: FWBI) and
HOOKIPA Pharma (Nasdaq: HOOK) and she is chairperson of the audit
committee and a member of the compensation committees for both
companies. She most recently served as Executive Vice President,
CFO and Chief Business Development Officer at CinCor Pharma, Inc.,
where she led the company’s successful initial public offering and
follow-on financing in 2022. AstraZeneca acquired CinCor in
February.
Ms. Coelho’s experience also includes serving as Executive Vice
President and CFO at BioDelivery Sciences International, Inc.,
which was acquired by Collegium Pharmaceuticals in 2022, and as CFO
at Balchem Corporation and Diversey, Inc. She held a series of
senior financial and executive roles at Sealed Air Corporation,
Mars, Inc. and Novartis Pharmaceuticals, where for seven years she
held roles of increasing responsibility including as finance lead
for the oncology hematology franchise and later leading global
oncology development finance.
“Omisirge has great commercial potential and the opportunity to
fill a critical need for patients in need of stem cell transplant,”
said Ms. Coelho. “I’m excited to work with the team to help support
Omisirge’s launch and find a partner that can help it fulfill its
promise.”
Ms. Coelho earned an MBA in Finance from IBMEC in Brazil and
Bachelor of Arts degrees in Economics and International Relations,
summa cum laude, from The American University School of
International Service in Washington, DC.
Omisirge® (omidubicel-onlv) was recently approved by the U.S.
Food and Drug Administration for patients with hematologic
malignancies who are planned for allogeneic hematopoietic stem cell
transplantation. Please see full Prescribing Information,
including the Boxed Warning.
About Gamida Cell
Gamida Cell is a cell therapy pioneer working to turn cells into
powerful therapeutics. The company’s proprietary nicotinamide (NAM)
technology leverages the properties of NAM to enhance and expand
cells, creating allogeneic cell therapy products and candidates
that are potentially curative for patients with hematologic
malignancies. These include Omisirge®, an FDA-approved nicotinamide
modified allogeneic hematopoietic progenitor cell therapy, and
GDA-201, an intrinsic NK cell therapy candidate being investigated
for the treatment of hematologic malignancies. For additional
information, please visit www.gamida-cell.com or follow
Gamida Cell on LinkedIn, Twitter, Facebook or
Instagram.
Omisirge® is a registered trademark of Gamida Cell Inc. © 2023
Gamida Cell Inc. All Rights Reserved.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995, including with respect to the potentially life-saving or
curative therapeutic and commercial potential of Omisirge®
(omidubicel-onlv), the company’s plans for commercial or strategic
partnerships to support the launch of Omisirge. Any statement
describing Gamida Cell’s goals, expectations, financial or other
projections, intentions or beliefs is a forward-looking statement
and should be considered an at-risk statement. Such statements are
subject to a number of risks, uncertainties and assumptions
including those related to clinical, scientific, regulatory and
technical developments and those inherent in the process of
developing and commercializing product candidates that are safe and
effective for use as human therapeutics. In light of these risks
and uncertainties, and other risks and uncertainties that are
described in the Risk Factors section and other sections of Gamida
Cell’s Quarterly Report on Form 10-Q, filed with the Securities and
Exchange Commission (SEC) on May 15, 2023, and other filings that
Gamida Cell makes with the SEC from time to time (which are
available at http://www.sec.gov), the events and
circumstances discussed in such forward-looking statements may not
occur, and Gamida Cell’s actual results could differ materially and
adversely from those anticipated or implied thereby. Although
Gamida Cell’s forward-looking statements reflect the good faith
judgment of its management, these statements are based only on
facts and factors currently known by Gamida Cell. As a result, you
are cautioned not to rely on these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230522005370/en/
Investor and Media Contact: Dan Boyle Orangefiery
media@orangefiery.com 1-818-209-1692
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Apr 2024 to May 2024
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From May 2023 to May 2024